Reference List

     

    

Reference List
  1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15-25.
  2. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72:1037-1047.
  3. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007;21:929-942.
  4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-2219.
  5. Cooney JK, Law RJ, Matschke V, et al. Benefits of exercise in rheumatoid arthritis. J Aging Res. 2011;2011:681640.
  6. Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clin Exp Immunol. 2006;143:1-5.
  7. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am. 2007;33:57-70.
  8. Stolt P, Källberg H, Lundberg I, et al. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2005;64:582-586.
  9. de Souza MC, de Ávila Fernandes E, Jones A, et al. Assessment of cervical pain and function in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30:831-836.
  10. Al-Tubaikh JA. Internal Medicine: An Illustrated Radiological Guide. Heidelberg: Springer-Verlag; 2010; 250-257.
  11. Haugeberg G, Emery P. Value of dual-energy x-ray absorptiometry as a diagnostic and assessment tool in early rheumatoid arthritis. Rheum Dis Clin North Am. 2005;31:715-728.
  12. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol. 2005;140:195-204.
  13. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-411.
  14. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:885-906.
  15. Verstappen SM, Symmons DP. What is the outcome of RA in 2011 and can we predict it? Best Pract Res Clin Rheumatol. 2011;25:485-496.
  16. Kumar N, Marshall NJ, Hammal DM, et al. Causes of death in patients with rheumatoid arthritis: comparison with siblings and matched osteoarthritis controls. J Rheumatol. 2007;34:1695-1698.
  17. Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25:469-483.
  18. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:871-883.
  19. Shih M, Hootman JM, Strine TW, et al. Serious psychological distress in U.S. adults with arthritis. J Gen Intern Med. 2006;21:1160-1166.
  20. Pisu M, James N, Sampsel S, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology. 2005;44:781-788.
  21. Lemp MA. Dry eye (Keratoconjunctivitis Sicca), rheumatoid arthritis, and Sjögren's syndrome. Am J Ophthalmol. 2005;140:898-899.
  22. Patel SJ, Lundy DC. Ocular manifestations of autoimmune disease. Am Fam Physician. 2002;66:991-998.
  23. Iliou C, Anthis N, Tsifetaki N, et al. Clinical images: Corneal melt in a woman with longstanding rheumatoid arthritis. Arthritis Rheum. 2012;64:253.
  24. Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum. 2006;54:642-648.
  25. Chou CW, Chang SC. Pleuritis as a presenting manifestation of rheumatoid arthritis: diagnostic clues in pleural fluid cytology. Am J Med Sci. 2002;323:158-161.
  26. Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol. 2008;35:1009-1014.
  27. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:907-927.
  28. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
  29. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-346.
  30. West S. In: Rheumatology Secrets. 2nd ed. Philadelphia, PA: Hanley and Belfus; 2002; 123.
  31. Caramaschi P, Biasi D, Colombatti M, et al. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int. 2006;26:209-214.
  32. Tan YK, Conaghan PG. Imaging in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25:569-584.
  33. Horton SC, Walsh CA, Emery P. Established rheumatoid arthritis: rationale for best practice: physicians’ perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol. 2011;25:509-521.
  34. Ishikawa H, Hashimoto H, Yano E. Patients’ preferences for decision making and the feeling of being understood in the medical encounter among patients with rheumatoid arthritis. Arthritis Rheum. 2006;55:878-883.
  35. Sharpe L, Allard S, Sensky T. Five-year followup of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum. 2008;59:311-316.
  36. Cameron M, Gagnier JJ, Little CV, et al. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: rheumatoid arthritis. Phytother Res. 2009;23:1647-1662.
  37. Zhang P, Li J, Han Y, et al. Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review. Rheumatol Int. 2010;30:713-718.
  38. Stamp LK, James MJ, Cleland LG. Diet and rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum. 2005;35:77-94.
  39. O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591-2602.
  40. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62:1515-1526.
  41. Drugs@FDA. U.S. Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed April 25, 2012.
  42. Hill CL. Leflunomide-induced peripheral neuropathy: rapid resolution with cholestyramine wash-out. Rheumatology. 2004;43:809.
  43. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol. 2000;27:623-629.
  44. Hasan U. Tumour necrosis factor inhibitors--what we need to know. N Z Med J. 2006;119:U2336.
  45. Lee SJ, Kavanaugh A. Biologic agents in rheumatology: safety considerations. Rheum Dis Clin North Am. 2006;32(suppl 1):3-10.
  46. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-516.
  47. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-3329.
  48. Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11:R170.
  49. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964-975.
  50. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210-221.
  51. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1939.
  52. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77-87.
  53. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-2806.
  54. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37:917-927.
  55. Kiely PD, Deighton C, Dixey J, et al. Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals. Rheumatology. 2012;51:24-31.
  56. Kremer JM, Fleischmann RM, Halland A, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study. Paper presented at: 72nd Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals; October 25-29, 2008; San Francisco, CA. Abstract L14.
  57. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med. 2007;46:771-774.
  58. Coffey G, Deguzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012;340:350-359.
  59. Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis - the kinase inhibitors. Bull NYU Hosp Jt Dis. 2011;69:233-237.
  60. Saag KG, et al. Arthritis and Rheumatism. 2008;59:762-784.
  61. Garneau KL, Iversen MD, Tsao H, et al. Primary care physicians’ perspectives towards managing rheumatoid arthritis: room for improvement. Arthritis Res Ther. 2011;13:R189.
  62. van den Bemt BJ, van den Hoogen FH, Benraad B, et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36:2164-2170.
  63. Fitzcharles MA, DaCosta D, Ware MA, et al. Patient barriers to pain management may contribute to poor pain control in rheumatoid arthritis. J Pain. 2009;10:300-305.
  64. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32:913-919.
  65. Pincus T, Sokka T. Quantitative measures to assess patients with rheumatic diseases: 2006 update. Rheum Dis Clin North Am. 2006;32(suppl 1):29-36.
  66. Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res. 2010;62:181-189.
  67. Farheen K, Agarwal SK. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm. 2011;17(suppl B):S09-S13.